Pandemic vaccines: Promises and pitfalls

Medical Journal of Australia

Volumn 185, Issue 10 SUPPL., 2006, Pages

  Booy, Robert ^a   Brown, Lorena E ^b   Grohmann, Gary S ^c,d   MacIntyre, C Raina ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DEATH; DEFECTIVE VIRUS; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EGG; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; REGISTRATION; RESPIRATORY TRACT INFECTION; TISSUE CULTURE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

EID: 34447568705     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00710.x     Document Type: Article

References (16)

1. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. Wkly Epidemiol Rec 2006; 81: 328-330.
2. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343-1351.
3. Bresson J-L, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367: 1657-1664.
4. Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194: 159-167.
5. GSK's H5N1 flu vaccine achieves high response at low dose. PharmaWeek 2006; 26 Jul. http://www.pharmaweek.com/TopNews/GSK's%20H5N1.asp (accessed Oct 2006).
6. Abbott T. Infectious diseases conference, pandemic preparedness [speech notes). 2 May 2005. http://www.health.gov.au/internet/ministers/ publishing.nsf/Content/health-mediarel-yr2005-ta-abbsp020505.htm (accessed Aug 2006).
7. World Health Organization. Avian influenza - situation in Indonesia - update 35. 3 October 2006. http://www.who.int/csr/don/2006_10_03/en/ index.html (accessed Oct 2006).
8. Global Advisory Committee on Vaccine Safety, 6-7 June, 2006. Wkly Epidemiol Rec 2006; 81: 273-276.
9. Watanabe T, Watanabe S, Neumann G, et al. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 2002; 76: 767-773.
10. Talon J, Salvatore M, O'Neill RE, et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci U S A 2000; 97: 4309-4314.
11. Watanabe T, Watanabe S, Kida H, Kawaoka Y. Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology 2002; 299: 266-270.
12. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine 2005; 23 Suppl 1: S26-S38.
13. Brands R, Visser J, Medema J, et al. Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 1999; 98: 93-100.
14. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18: 244-251.
15. Kodihalli S, Goto H, Kobasa DL, et al. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999; 73: 2094-2098.
16. Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004; 101: 15440-15445.